{
    "key_points": [
        "FDA issues emergency use authorization (EUA) for the Janssen COVID-19 Vaccine for individuals 18 years and older.",
        "This is the third COVID-19 vaccine authorized in the U.S. to fight the pandemic that has claimed over half a million lives in the country.",
        "Janssen COVID-19 Vaccine uses adenovirus type 26 (Ad26) to deliver genetic material for the spike protein of the SARS-CoV-2 virus, triggering an immune response.",
        "The vaccine is administered in a single dose and has demonstrated approximately 67% effectiveness in preventing moderate to severe COVID-19.",
        "Safety data includes analysis from an ongoing study with 43,783 participants, showing common side effects like injection site pain and fatigue.",
        "Manufacturers and vaccination providers are required to report serious adverse events and certain other cases to the Vaccine Adverse Event Reporting System (VAERS).",
        "Effectiveness data shows the vaccine is approximately 77% effective in preventing severe/critical COVID-19 14 days post-vaccination.",
        "Data on long-term protection and transmission prevention by the vaccine are not yet available.",
        "Janssen Biotech Inc. has submitted a pharmacovigilance plan to monitor the vaccine's safety and is expected to continue clinical trials for additional data.",
        "The EUA allows the use of the Janssen COVID-19 Vaccine during the declared public health emergency; it is different from full FDA approval."
    ],
    "spokespersons": [
        "Janet Woodcock, M.D. (Acting FDA Commissioner)",
        "Peter Marks, M.D., Ph.D. (Director of the FDA's Center for Biologics Evaluation and Research)"
    ],
    "article_type": "government agency statement",
    "dateline": "",
    "audience": "general public",
    "stance": "neutral"
}